J M Pagel


Affiliation: Fred Hutchinson Cancer Research Center
Country: USA


  1. Balkin E, Kenoyer A, Orozco J, Hernandez A, Shadman M, Fisher D, et al. In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model. Cancer Res. 2014;74:5846-54 pubmed publisher
    ..Overall, our findings offer a preclinical proof of concept for the use of CLI techniques in tandem with currently available clinical diagnostic tools. ..
  2. request reprint
    Pagel J, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003;101:2340-8 pubmed
    ..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic. ..
  3. request reprint
    Pagel J, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 2007;67:5921-8 pubmed
    ..Improvements in tumor-to-normal organ ratios of radioactivity cannot be achieved using directly labeled Abs in combination but may be afforded by novel pretargeting methods. ..
  4. Pagel J, Kenoyer A, Bäck T, Hamlin D, Wilbur D, Fisher D, et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood. 2011;118:703-11 pubmed publisher
    ..These data suggest that anti-CD45 PRIT using an ?-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia. ..
  5. Pagel J, Appelbaum F, Eary J, Rajendran J, Fisher D, Gooley T, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184-91 pubmed
    ..39-1.08; P = .09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and phase 2 results are sufficiently encouraging to warrant further study...
  6. Pagel J, Orgun N, Hamlin D, Wilbur D, Gooley T, Gopal A, et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood. 2009;113:4903-13 pubmed publisher
    ..We hypothesize that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of survival for patients with relapsed lymphomas compared with currently available treatment strategies. ..
  7. Pagel J, Gooley T, Rajendran J, Fisher D, Wilson W, Sandmaier B, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009;114:5444-53 pubmed publisher
    ..This study was registered at www.clinicaltrials.gov as #NCT00008177...